about
Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failureA European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical PharmacogenomicsCompound heterozygosity of two missense mutations in the NADH-cytochrome b5 reductase gene of a Polish patient with type I recessive congenital methaemoglobinaemia.Investigating the effects of statins on cellular lipid metabolism using a yeast expression system.Transcriptional profiling of left ventricle and peripheral blood mononuclear cells in a rat model of postinfarction heart failure.Altered gene expression pattern in peripheral blood mononuclear cells in patients with acute myocardial infarction.The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.The rs12526453 Polymorphism in an Intron of the PHACTR1 Gene and Its Association with 5-Year Mortality of Patients with Myocardial Infarction.Two novel C-terminal frameshift mutations in the β-globin gene lead to rapid mRNA decay.Molecular evidence that exercise training has beneficial effects on cardiac performance.Will global transcriptome analysis allow the detection of novel prognostic markers in coronary artery disease and heart failure?The use of real-time PCR technique in the detection of novel protein 4.2 gene mutations that coexist with thalassaemia alpha in a single patient.Theoretical model of reticulocyte to erythrocyte shape transformation.Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.The first reported case of G6PD deficiency due to Seoul mutation in Poland.A novel mutation in the glucose-6-phosphate dehydrogenase gene in a subject with chronic nonspherocytic hemolytic anemia--characterization of enzyme using yeast expression system and molecular modeling.Characterization of a novel mutation in the NADH-cytochrome b5 reductase gene responsible for rare hereditary methaemoglobinaemia type I.miR-22-5p revealed as a potential biomarker involved in the acute phase of myocardial infarction via profiling of circulating microRNAs.Molecular analysis of three novel G6PD variants: G6PD Pedoplis-Ckaro, G6PD Piotrkow and G6PD Krakow.Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA.Genetic engineering and molecular characterization of yeast strain expressing hybrid human-yeast squalene synthase as a tool for anti-cholesterol drug assessment.Diversity of thalassemia variants in Poland - screening by real-time PCR.Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction.Several mutations including two novel mutations of the glucose-6-phosphate dehydrogenase gene in Polish G6PD deficient subjects with chronic nonspherocytic hemolytic anemia, acute hemolytic anemia, and favismMolecular and haematological studies of four families with hereditary spherocytosis resulting from band 3 deficiencyA1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatmentTheoretical model of thalassemic erythrocyte shape transformationCoexistence of Gilbert syndrome with hereditary haemolytic anaemiasInterindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction
P50
Q28262080-18308608-EA47-4E51-BD04-9F56E96B5103Q28554199-1AB73FCB-8522-4C85-BEBA-143A1DBAF00AQ30332864-E256C660-CBFE-46AB-B56A-9DB7059F563DQ33521217-6B5B90BA-ED36-48FE-A582-96D8DD7E37EEQ34481362-F918B556-9CC9-4244-B235-05D40E3E3BC1Q34490950-6DC30A28-26FA-43CF-AC07-7251EA1FD362Q35017735-0AD13F23-4D68-4515-861C-7B0407CBA5CFQ35667272-9C398793-6836-4B31-9F6F-390CF047FB26Q36396254-8F465FDF-2CF9-4DF0-82DB-1EED8403E62CQ37027249-254D90D1-F27A-4BA6-98A3-519077157205Q37389353-4B332D50-8E5C-496C-8748-DBB6269A8F7FQ37420161-5B5EB043-5AAE-4694-888A-0B612CE32CA3Q40302540-38D96123-DAE7-47B1-8962-A81709B64157Q42320992-D1261D5F-1C14-49A7-ABE7-B3203D33F3D6Q42375139-B905B648-752B-4570-AA33-40E5F508E148Q44752260-093404D6-84BA-48C3-871C-160D519AADCCQ44829660-F429FBF3-3A6F-4195-9491-267365CC51B2Q46507195-916E55B1-847A-4D3F-BFE4-E76D90487CA6Q46861084-0E41E33F-4EA1-49B2-9C6C-F974A7D847A5Q50605425-5B939DB5-5F21-468E-B900-12460014D59CQ51565685-D0BCCEF6-9FE7-49C5-8A1E-BAF2FB58FE9BQ54505505-AA70EBC1-2680-427A-9972-034DDE775822Q55501361-7E2AD442-D262-476B-9FCF-A60055809922Q73205340-DA0ED46A-6C24-415A-BF3C-802E2DAECA9EQ80129953-3DDE1F9E-D3F6-4B51-B114-27BF8862761AQ80580628-69451D86-AFDA-43B4-B725-6F010F840531Q81695121-F5CB5901-EDA8-40DB-92C1-CDF60B3B9CC4Q84066552-E4719FEC-4937-4825-96EA-257A48779C90Q86961817-5D8C363E-C6AB-473A-A32B-D33EB4BF8597
P50
description
Polish geneticist
@en
Pools onderzoekster
@nl
cercetătoare poloneză
@ro
chercheuse polonaise
@fr
investigadora polaca
@es
investigadora polaca
@gl
investigadora polonesa
@ca
polnische Forscherin
@de
polska genetyk
@pl
ricercatora polacca
@it
name
Beata Burzynska
@es
Beata Burzynska
@nl
Beata Burzyńska
@ast
Beata Burzyńska
@ca
Beata Burzyńska
@cs
Beata Burzyńska
@de
Beata Burzyńska
@en
Beata Burzyńska
@fr
Beata Burzyńska
@ga
Beata Burzyńska
@gl
type
label
Beata Burzynska
@es
Beata Burzynska
@nl
Beata Burzyńska
@ast
Beata Burzyńska
@ca
Beata Burzyńska
@cs
Beata Burzyńska
@de
Beata Burzyńska
@en
Beata Burzyńska
@fr
Beata Burzyńska
@ga
Beata Burzyńska
@gl
altLabel
Beata Burzynska
@en
Beata Iwona Burzyńska
@en
Beata Iwona Burzyńska
@pl
prefLabel
Beata Burzynska
@es
Beata Burzynska
@nl
Beata Burzyńska
@ast
Beata Burzyńska
@ca
Beata Burzyńska
@cs
Beata Burzyńska
@de
Beata Burzyńska
@en
Beata Burzyńska
@fr
Beata Burzyńska
@ga
Beata Burzyńska
@gl
P214
P1153
6602770312
P1412
P1559
Beata Burzyńska
@pl
P21
P214
P27
P31
P3124
P496
0000-0003-1595-0036
P734
P7859
viaf-313516296